2012/3-4 GaBI Journal Table of Contents

Published in: Volume 1 / Year 2012 / Issue 3-4
Category: 2012/3-4 GaBI Journal Table of Contents
Visits: 2376 total, 1 today

Contents

Editor’s Letter

Latest features in GaBI Journal, 2012, issue 3-4

Letters to the Editor

A bioethicist’s view of the use of biosimilars

A clinician’s view of the ethics of the use of biosimilars

Editorial

Generics policies–a globally-relevant implementation challenge

Reference price systems: stakeholder dialogue and involvement

Commentary

Statin generics: no differences in efficacy after switching

Pharmacovigilance of biosimilars: challenges and possible solutions

Original Research

Saving money in the European healthcare systems with biosimilars

Review Article

Reference pricing systems in Europe: characteristics and consequences

Perspective

Terminology for biosimilars–a confusing minefield

Health professionals in the risk communication process on counterfeit medicines

Special Report

The MEDICRIME Convention: criminalising the falsification of medicines and similar crimes

Guidelines

ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities

Conference Report

The potential of generics policies: more room for exploitation–PPRI Conference Report

News

Austria could save Euros 256 million by using more generics

Abstracted Scientific Content

The potential for doctors to contribute to biosimilar guidelines

 

Go Back Print

Leave a Reply